Menu
Recruiting NCT05002023

PRINCE Study - Cohort Study of Healthy Pregnant Women Followed by the Assessment of Children´s Health and Immunity

Observational Pregnancy Immune System Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Pregnancy, Immune System Disorder. Basic parameters: 18 years — 50 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Germany
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

PRINCE - PRenatal Identification of Childrens HEalth

Overview

In the PRINCE study we recruit healthy but also diseased pregnant women into a cohort study, followed by the assessment of children´s health and immunity at birth and during the first 10 years of life. This unique cohort allows for testing the impact of prenatal challenges on children´s health.

Detailed description

Children´s Health is critically dependent of the prenatal well-being of the mother, and a number of observational studies have identified an impaired immunity in children upon prenatal challenges, such as stress perception, medication, nutrition or infection. However, concerted, in-depth studies assessing how such prenatal challenges may alter fetal development and subsequently children´s health in humans are largely lacking. In the present project, we address this limitation by recruiting healthy, but also diseased pregnant women into a cohort study, followed up by the assessment of children´s health and immunity at birth and during the first ten years of life.

Study participants are recruited early in the first trimester (12-15 weeks of gestation). By means of data security all participants receive a study number. Data processing into the data base (Redcap) is performed under this pseudonym.

During the first visit, the study team explains the enrollment conditions and the participants are asked to give their consent. Study visits include the documentation of clinically important conditions, sonographic examination of the fetus, assessment of mother´s height and weight as well as blood collection (21 ml) of the mother. Additionally we document any kind of medication-intake and nutrition data, and the participants are asked to fill in a psychometric questionnaire. Study visits are scheduled according to the week of gestation, i.e. around 13th, 20th (ultrasound only), 24th, 28th, 34th week. If women give birth in our clinic, we are able to collect cord blood after birth.

Blood samples are processed immediately and stored in our laboratory under Biobank-conditions.

Primary outcome measures

  • Types of allergic diseases in childhood [Time frame: 10 years follow up]
Secondary outcome measures (3)
  • influences during pregnancy that potentially affect children´s health [Time frame: 10 years follow up]
  • influences during pregnancy that potentially affect children´s health [Time frame: 10 years follow up]
  • influences during pregnancy that potentially affect children´s health [Time frame: 10 years follow up]

Eligibility criteria

Inclusion criteria

  • Pregnant women
  • >18 years of age
  • able to understand and sign the papers of consent
  • singleton pregnancy

Exclusion Criteria: :

  • <18 years of age
  • unable to give consent
  • multiple pregnancy
  • nicotine abuse
  • fetal aberration

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

Germany · 1 center
  • Universitätsklinikum Hamburg-Eppendorf — Hamburg

Identifiers

NCT: NCT05002023 · PV3694

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗